Phase
Condition
Pneumonia
Lung Injury
Acute Respiratory Distress Syndrome (Ards)
Treatment
salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)
Clinical Study ID
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
• Age > 18, < 90 years
Non-intubated critically ill patients with AHRF due to pneumonia (diagnosis isbased on the presence of infiltrates on chest X-ray and the onset of clinicalsigns of infection less than 7 days earlier)
PaO2/FiO2 ≤ 300 mmHg
Patients receiving oxygen therapy
Exclusion
Exclusion Criteria:
• Age < 18 years
Hypercapnia (PaCO2 > 50 mmHg)
Hemodynamic instability (Systolic blood pressure < 90 mmHg or Mean arterialpressure < 60 or high dose of vasoactive drugs)
Tachycardia or tachyarrhythmia (HR > 130 b/min)
Known allergy or intolerance to salbutamol
Patient has received inhaled therapy with short-acting beta 2 agonists < 8hours before or with long-acting beta 2 agonists < 24 hours before
Acute exacerbation of COPD or bronchial asthma
Cardiogenic pulmonary edema
GCS ≤ 12
Contraindication for EIT (e.g. ICD)
Pregnancy
Patient refuses to participate
Study Design
Study Description
Connect with a study center
Azienda ospedaliera Universitaria di Ferrara
Ferrara, 44121
ItalySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.